Urate Management in CKD: Evaluating Treat-to-Target Strategies

Clinicians often debate the benefits of lowering uric acid in patients without gout. Effective urate management in CKD is a cornerstone of metabolic care, yet evidence for treating asymptomatic hyperuricemia remains inconsistent. A recent target trial emulation by Liu Q et al. investigated whether intensive urate-lowering therapy (ULT) truly benefits kidney function. Consequently, this study provides vital insights for nephrologists managing stage G3-G4 chronic kidney disease. However, the results suggest that aggressive targets might not be necessary for all patients.

Study Findings: No Significant Renal Benefit

The research team utilized a clone-censor-weight approach to minimize selection biases in their analysis of 2,092 adults. Specifically, they compared a treat-to-target strategy against standard usual care. The investigators focused on critical endpoints such as kidney failure and significant eGFR decline. Surprisingly, the results indicated that the intensive strategy did not offer superior protection for kidney health. Therefore, the findings align with several recent clinical trials that question the utility of ULT in asymptomatic patients. Moreover, the lack of benefit was consistent across various patient subgroups.

Challenges in Urate Management in CKD

Managing high urate levels is challenging because observational data often link hyperuricemia to disease progression. However, interventional studies frequently fail to replicate these associations. Notably, the 2024 KDIGO guidelines now recommend against using urate-lowering agents solely to delay CKD progression in asymptomatic individuals. This shift emphasizes the need for personalized medicine. Furthermore, clinicians should focus on evidence-based therapies like SGLT2 inhibitors and blood pressure control rather than aggressive urate targets for those without gout symptoms. In addition, routine monitoring of urate remains important but treatment should be symptom-driven. Thus, the clinical focus is shifting toward holistic renal care.

Frequently Asked Questions

Should doctors treat asymptomatic hyperuricemia in CKD stage 3?

Current guidelines and recent trials suggest that initiating urate-lowering therapy in asymptomatic patients does not significantly slow kidney disease progression. Therefore, routine treatment is generally not recommended unless the patient develops symptoms like gout or certain types of kidney stones.

Are there risks to intensive urate-lowering therapy?

Yes, intensive therapy can lead to adverse effects, drug interactions, and increased costs. Specifically, medications like allopurinol require careful dosing in CKD to avoid hypersensitivity reactions. Consequently, the risks often outweigh the unproven renal benefits in asymptomatic cases.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Liu Q et al. A treat-to-target urate management strategy does not improve kidney outcome in patients with chronic kidney disease and asymptomatic hyperuricemia: a target trial emulation. Ann Med. 2026 Dec undefined. doi: 10.1080/07853890.2026.2668232. PMID: 42096265.


2. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.


3. Nie S, et al. Urate-lowering therapy and kidney outcomes in patients with chronic kidney disease and hyperuricemia. Signal Transduct Target Ther. 2025;10:399.